Nxera Pharma Submits Marketing Authorization Application For Daridorexant In South Korea
04/03/2026 06:36
March 4 (Reuters) - Nxera Pharma Co Ltd 4565.T: NXERA PHARMA CO LTD: NXERA PHARMA SUBMITS MARKETING AUTHORIZATION APPLICATION FOR DARIDOREXANT IN SOUTH KOREA Source text: ID:nTSod8c7d6 Further company coverage: 4565.T (Reporting by Tokyo Newsroom) ((+81345201189;))
Recent news on Nxera Pharma
See all newsNxera Pharma Submits Marketing Authorization Application For Vamorolone In South Korea For Treatment Of Duchenne Muscular Dystrophy
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Nxera Pharma - Entered Into Exclusive License, Supply And Commercialization Agreement With Synmosa For Quviviq Across Eight Asia-Pacific Markets
Brief: Nxera Announces Successful Resolution Of Minig Patent Infringement Action
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up